Researchers at the University of Notre Dame are working on a new approach to treat Cytomegalovirus (CMV), the most common congenital infection worldwide and the leading infectious cause of birth defects, according to the university.

CMV is widespread but little-known. In the United States, one in three children will have been infected by age five, and more than half of adults by age 40, Notre Dame reported. Most people experience no symptoms, but the virus can cause severe, life-threatening illness in those with weakened immune systems — including newborns, pregnant women, and recipients of organ, stem cell, or bone marrow transplants.

The only FDA-approved drug for serious CMV infections is Ganciclovir, but it carries significant risks. The medication can be toxic and may accumulate to poisonous levels in the body, Notre Dame said. As a result, transplant patients can only use it for limited periods, and it is not recommended for infants or pregnant women. Pregnant women with CMV face an elevated risk of miscarriage or passing the infection to their fetus.

Two Notre Dame researchers — Pilar Perez Romero, an associate professor in the Department of Biological Sciences, and Prakash Nallathamby, associate director of the Berthiaume Institute for Precision Health — have teamed up to develop a technology that could reduce Ganciclovir's toxicity. Their project is funded by the National Institutes of Health and aligns with the university's Bioengineering & Life Sciences Initiative, Notre Dame reported.

"Once you have CMV, you have it for life. You can even reactivate the latent virus in your body if you experience immunity suppression, like in pregnancy or as a transplant patient," Perez Romero said in a university statement. "We want to find an alternative treatment option."

Perez Romero's lab initially explored using antibodies as an alternative to Ganciclovir. Antibodies act as signals for macrophage cells, which destroy viruses and infected cells. To obtain CMV-specific antibodies, Perez Romero worked with the Indiana BioBank to access blood samples from transplant patients, who are especially vulnerable to multiple CMV infections after transplantation, according to Notre Dame.

Graduate students Addison Hill and Kathryn Currie isolated antibodies from those samples and discovered that when the antibodies reached CMV-infected cells, the virus absorbed them — a defense mechanism that hides the antibodies from macrophage cells, Notre Dame reported.

Perez Romero then approached Nallathamby, a nanoparticle engineer, to see if his patent-pending technology — originally designed to treat chronic wound infections using resorbable polymer nanoparticles made of FDA-approved materials — could be adapted. She asked whether these particles, which steadily release antibiotics over three to five days, could encapsulate Ganciclovir and deliver it only to CMV-infected cells.

Nallathamby said encapsulating the drug was feasible, but the challenge lies in timing: the nanoparticles must reach infected cells before releasing the medication too quickly.

"Imagine the nanoparticles as a cotton candy ball with colored sugar inside it, but the sugar is the Ganciclovir. Now you attach a key — the isolated antibody — that fits one specific lock on a CMV-infected cell. You toss the whole thing into a pool of water, representing the body, and need it to reach the lock before the cotton candy dissolves," Nallathamby said. "That is the challenge. But we do have ways to control the dissolution rate."

The strategy exploits CMV's own defense mechanism: as an infected cell draws in the antibody, it would also engulf the attached nanoparticle. Once inside, the nanoparticle would break down and release Ganciclovir directly. If successful, this approach could concentrate the drug inside infected cells while reducing exposure elsewhere in the body, lowering the risk of toxicity, Notre Dame reported.

Perez Romero and Nallathamby are currently developing a laboratory proof of concept. Their eventual goal is to create a treatment option that can help the most vulnerable patients — pregnant women, infants, and transplant recipients — safely access the life-saving drug, according to the university.